Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1634 SEK | +2.12% | +2.12% | -33.44% |
Feb. 23 | Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
2023 | Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study | CI |
Business Summary
Number of employees: 8
Sales per Business
SEK in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Mitochondrial Medicine
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -79.47% |
Sales per region
SEK in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Sweden
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -79.47% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ellen Donnelly
CEO | Chief Executive Officer | 50 | 21-02-02 |
Eskil Elmér
FOU | Founder | 54 | 00-01-31 |
Director of Finance/CFO | 57 | 13-11-30 | |
Dag Nesse
CTO | Chief Tech/Sci/R&D Officer | - | 23-01-31 |
Magnus Hansson
CTO | Chief Tech/Sci/R&D Officer | 48 | 07-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 69 | 16-04-27 | |
David Bejker
BRD | Director/Board Member | 49 | 17-04-26 |
Eskil Elmér
FOU | Founder | 54 | 00-01-31 |
Roger Franklin
BRD | Director/Board Member | 45 | 20-05-19 |
Denise Goode
BRD | Director/Board Member | 66 | 18-04-26 |
Director/Board Member | 64 | 17-04-26 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,056,299,165 | 930,212,762 ( 88.06 %) | 0 | 88.06 % |
Company contact information
Sector
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-33.44% | 15.45M | |
-3.39% | 102B | |
+2.61% | 96.09B | |
-1.02% | 22.05B | |
-18.14% | 20.81B | |
-6.87% | 19.06B | |
-40.70% | 16.05B | |
-26.89% | 14.01B | |
+1.12% | 13.38B | |
+22.25% | 11.01B |
- Stock Market
- Equities
- ABLI Stock
- Company Abliva AB